Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Lightchain Capital LLC is a venture capital fund established in 2018 by Rodger Riney, the founder of Scottrade, a brokerage firm sold to TD Ameritrade in 2017 for approximately $4 billion. Based in St. Louis, Missouri, this single-family office focuses on early-stage investments in life sciences, particularly in cancer therapeutics and diagnostics. Riney’s personal experience as a multiple myeloma patient informs the fund's mission to accelerate scientific cancer research and improve patient outcomes.
The firm operates with a mission-driven approach, prioritizing investments that align with enhancing cancer treatment. Lightchain Capital has built a portfolio of seven companies, reflecting its commitment to supporting innovations in the life sciences sector. The firm is structured as a family office, allowing for a more personalized investment strategy compared to traditional venture capital funds.
Lightchain Capital primarily invests in early-stage life sciences and software companies, with a strong emphasis on cancer therapeutics and diagnostics. The fund targets investments in companies that are seeking multiple rounds of financing and collaboration opportunities. This approach allows Lightchain to support innovations that can significantly impact cancer treatment and patient care.
The firm focuses on sectors such as biotech and healthcare, specifically targeting companies developing treatments for multiple myeloma and related blood cancers. Lightchain Capital's investment strategy includes participating in seed through Series C funding rounds, indicating a willingness to engage deeply with its portfolio companies. The firm seeks founders who are committed to advancing scientific research and improving patient outcomes, aligning with its mission-driven investment thesis.
Lightchain Capital's portfolio includes seven notable companies, each contributing to advancements in life sciences and cancer treatment:
Among these, C4 Therapeutics is notable for its focus on oncology and is publicly listed on NASDAQ. Geneoscopy has made strides in colorectal cancer early detection, securing a $105 million Series C funding round. Wugen has raised $115 million in private equity to advance its NK cell therapy for blood cancers. This diverse portfolio reflects Lightchain Capital's commitment to impactful investments in the life sciences sector.
Rodger O. Riney - Founder; Riney founded Scottrade and built it into one of the largest U.S. discount brokerages over 37 years. His personal experience as a multiple myeloma patient drives the mission of Lightchain Capital.
Drew Dennison - Managing Director; Dennison brings extensive experience in venture capital and investment management, focusing on life sciences.
John Harry Wagner - Principal; Wagner has a background in biotechnology investments and has led several successful funding rounds in the sector.
Jenna McClary - Director of Accounting; McClary oversees financial operations and reporting for the firm, ensuring compliance and efficiency.
Danae Bednar - Executive Assistant/Office Manager; Bednar supports the team with administrative tasks and office management, facilitating smooth operations.
To pitch Lightchain Capital, startups should use the contact form available on their website at lightchain-capital.com. It is important to include a comprehensive pitch deck that outlines the company's mission, technology, market potential, and funding needs. The firm appreciates detailed information that demonstrates the startup's commitment to improving cancer treatment outcomes.
Response times may vary, but founders can expect to hear back regarding their pitch within a reasonable timeframe. Warm introductions are preferred, as they can enhance the likelihood of a favorable review.
As of October 2023, Lightchain Capital has been actively investing in notable life sciences companies, including C4 Therapeutics and Geneoscopy. The firm continues to focus on accelerating investments in scientific cancer research, particularly in the realm of multiple myeloma and related blood cancers.
Recent portfolio highlights include Wugen's successful $115 million private equity round and Geneoscopy's $105 million Series C funding, both of which underscore Lightchain Capital's commitment to supporting impactful innovations in cancer treatment.
What are Lightchain Capital's investment criteria?
Lightchain Capital focuses on early-stage life sciences and software companies, particularly those developing cancer therapeutics and diagnostics. The firm seeks opportunities in companies that require multiple rounds of financing and collaboration.
How can startups apply or pitch to Lightchain Capital?
Startups can pitch to Lightchain Capital through their website at lightchain-capital.com. It is advisable to include detailed information about the company's mission, technology, and market potential in the pitch deck.
What makes Lightchain Capital different from other investors?
Lightchain Capital operates as a single-family office, allowing for a mission-driven investment approach focused on improving cancer treatment outcomes. This personal commitment from founder Rodger Riney, a multiple myeloma patient, drives the fund's unique perspective.
What is the geographic scope of Lightchain Capital's investments?
The firm primarily invests in North America, with a strong focus on the United States.
What is the typical check size for investments made by Lightchain Capital?
While specific check sizes are not publicly disclosed, Lightchain Capital participates in larger institutional rounds, indicating significant check capacity, typically ranging from $23 million to $115 million.
What level of post-investment involvement does Lightchain Capital have?
Lightchain Capital actively engages with its portfolio companies, tracking board appointments, trial data, and partnerships to ensure alignment with its mission of improving cancer treatment outcomes.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.